A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Recent studies suggest that thousands of genes may contribute to breast cancer pathophysiologies when deregulated by genomic or epigenomic events. Here, we describe a model "system" to appraise the functional contributions of these genes to breast cancer subsets. In general, the recurrent genomic and transcriptional characteristics of 51 breast cancer cell lines mirror those of 145 primary breast tumors, although some significant differences are documented. The cell lines that comprise the system also exhibit the substantial genomic, transcriptional, and biological heterogeneity found in primary tumors. We show, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations.
Neve
Richard M
RM
Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA. rmneve@lbl.gov
Chin
Koei
K
Fridlyand
Jane
J
Yeh
Jennifer
J
Baehner
Frederick L
FL
Fevr
Tea
T
Clark
Laura
L
Bayani
Nora
N
Coppe
Jean-Philippe
JP
Tong
Frances
F
Speed
Terry
T
Spellman
Paul T
PT
DeVries
Sandy
S
Lapuk
Anna
A
Wang
Nick J
NJ
Kuo
Wen-Lin
WL
Stilwell
Jackie L
JL
Pinkel
Daniel
D
Albertson
Donna G
DG
Waldman
Frederic M
FM
McCormick
Frank
F
Dickson
Robert B
RB
Johnson
Michael D
MD
Lippman
Marc
M
Ethier
Stephen
S
Gazdar
Adi
A
Gray
Joe W
JW
D001943:Breast Neoplasms / Q000145:classification* / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D045744:Cell Line, Tumor; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D023281:Genomics; D006801:Humans; D009363:Neoplasm Proteins / Q000032:analysis
D009363:Neoplasm Proteins